- Home
- SUPV vs PSNL Comparison
SUPV vs PSNL Comparison
Compare SUPV & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPV | PSNL |
|---|---|---|
| Founded | 1887 | 2011 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 927.1M | 746.8M |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SUPV | PSNL |
|---|---|---|
| Price | $11.43 | $9.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $13.33 | $10.71 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 11-25-2025 | 02-26-2026 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $467,987,272.00 | $69,103,000.00 |
| Revenue This Year | $12.75 | N/A |
| Revenue Next Year | $45.23 | $20.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.54 | $2.83 |
| 52 Week High | $19.75 | $11.40 |
Technical Indicators
Market Signals| Indicator | SUPV | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 59.72 |
| Support Level | $11.05 | $7.72 |
| Resistance Level | $12.48 | $8.14 |
| Average True Range (ATR) | 0.63 | 0.50 |
| MACD | -0.08 | 0.10 |
| Stochastic Oscillator | 41.32 | 89.32 |
Price Performance
Historical ComparisonAbout SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.